

Outlook Therapeutics, Inc. Logo

Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

January 19, 2022

Live video webcast presentation on Tuesday, January 25th at 3:00 PM ET

ISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that [C. Russell Trenary III, President & Chief Executive Officer](#) will participate in the [Virtual Investor 2022 Top Picks Conference](#) on Tuesday, January 25, 2022 at 3:00 PM ET.

As part of the virtual event, Outlook Therapeutics will provide a corporate presentation, followed by a moderated interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at [virtualinvestorco.com](#). The Company will answer as many questions as possible during the event.

A [live video webcast](#) of the presentation will be available on the [Events](#) page of the [Investors](#) section of Outlook Therapeutics' website ([outlooktherapeutics.com](#)). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit [www.outlooktherapeutics.com](#).

CONTACTS:

Media Inquiries:

Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com



Source: Outlook Therapeutics, Inc.